These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10674848)

  • 21. [Cortical amaurosis and status epilepticus with acute porphyria].
    Wessels T; Blaes F; Röttger C; Hügens M; Hüge S; Jauss M
    Nervenarzt; 2005 Aug; 76(8):992-5, 997-8. PubMed ID: 15791420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atypical attack of acute intermittent porphyria--paresis but no abdominal pain.
    Andersson C; Nilsson A; Bäckström T
    J Intern Med; 2002 Sep; 252(3):265-70. PubMed ID: 12270008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of fluoxetine treatment in a case of acute intermittent porphyria.
    Mercan S; Karamustafalioglu O; Tanriverdi˙ N; Oba S
    Int J Psychiatry Clin Pract; 2003; 7(4):281-3. PubMed ID: 24930416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic dilemmas in acute intermittent porphyria. A case report.
    Periasamy V; al Shubaili A; Girsh Y
    Med Princ Pract; 2002; 11(2):108-11. PubMed ID: 12123102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case of acute intermittent porphyria.
    Ahmed M; Ahmed MS; Patwary MI; Miah MT; Hasan MK; Hossain SZ; Sultana B; Chakraborty SR
    Mymensingh Med J; 2015 Apr; 24(2):420-3. PubMed ID: 26007278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Many pitfalls in diagnosis of acute intermittent porphyria: a case report.
    Indika NLR; Kesavan T; Dilanthi HW; Jayasena KLSPKM; Chandrasiri NDPD; Jayasinghe IN; Piumika UMT; Vidanapathirana DM; Gunarathne KDAV; Dissanayake M; Jasinge E; Arachchi WK; Doheny D; Desnick RJ
    BMC Res Notes; 2018 Aug; 11(1):552. PubMed ID: 30071891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Acute intermittent porphyria in 2 Moroccan families. Clinical and biological study].
    Aquaron R; Zarrouck K; el Boussaki A; Acquaviva JE
    Rev Med Interne; 1996; 17(6):477-81. PubMed ID: 8758536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Acute intermittent porphyria (AIP)].
    Yano Y; Kondo M
    Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):136-8. PubMed ID: 9645024
    [No Abstract]   [Full Text] [Related]  

  • 29. Brain magnetic resonance imaging white-matter lesions and cerebrospinal fluid findings in patients with acute intermittent porphyria.
    Bylesjö I; Brekke OL; Prytz J; Skjeflo T; Salvesen R
    Eur Neurol; 2004; 51(1):1-5. PubMed ID: 14631121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute intermittent porphyria presenting with a subarachnoid haemorrhage.
    van Heyningen C; Simms DM
    Ann Clin Biochem; 2008 Nov; 45(Pt 6):610-1. PubMed ID: 18782811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Acute intermittent porphyria: a diagnostic dilemma].
    Gázquez Sisteré I; Luján Mavila K; Chordá Ribelles J; Touzón López C
    Gastroenterol Hepatol; 2010; 33(6):436-9. PubMed ID: 20435380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vitamin D-binding protein as a biomarker of active disease in acute intermittent porphyria.
    Serrano-Mendioroz I; Sampedro A; Mora MI; Mauleón I; Segura V; Enríquez de Salamanca R; Harper P; Sardh E; Corrales FJ; Fontanellas A
    J Proteomics; 2015 Sep; 127(Pt B):377-85. PubMed ID: 25979770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Yeast, creatinine and false diagnosis of porphyria.
    Schoenfeld N; Sztern M; Mamet R
    Cell Mol Biol (Noisy-le-grand); 1997 Feb; 43(1):81-8. PubMed ID: 9074792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of two nutritional hepatic markers (insulin-like growth factor 1 and transthyretin) in the clinical assessment and follow-up of acute intermittent porphyria patients.
    Delaby C; To-Figueras J; Deybach JC; Casamitjana R; Puy H; Herrero C
    J Intern Med; 2009 Sep; 266(3):277-85. PubMed ID: 19570056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyria.
    Marsden JT; Rees DC
    J Clin Pathol; 2014 Jan; 67(1):60-5. PubMed ID: 23908454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute intermittent porphyria: diagnosis per chance.
    Soundravally R; Goswami K; Nandeesha H; Koner BC; Sethuraman KR
    Indian J Pathol Microbiol; 2008; 51(4):551-2. PubMed ID: 19008594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.
    Sardh E; Harper P; Andersson DE; Floderus Y
    Eur J Intern Med; 2009 Mar; 20(2):201-7. PubMed ID: 19327613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study.
    Bylesjö I; Wikberg A; Andersson C
    Scand J Clin Lab Invest; 2009; 69(5):612-8. PubMed ID: 19401933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anesthesia in a child with homozygous porphobilinogen deaminase deficiency: a severe form of acute intermittent porphyria.
    Sheppard L; Dorman T
    Paediatr Anaesth; 2005 May; 15(5):426-8. PubMed ID: 15828996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute intermittent porphyria: psychosis as the only clinical manifestation.
    Ellencweig N; Schoenfeld N; Zemishlany Z
    Isr J Psychiatry Relat Sci; 2006; 43(1):52-6. PubMed ID: 16910386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.